Say Hello to Omnipod® 5
Omnipod 5 is now available in 14 markets: Australia, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Sweden, Switzerland, the U.K., and the U.S.
Managing type 1 diabetes just got easier for your patients. They can rely on the system that makes automated§ basal insulin delivery adjustments every 5 minutes—so they don’t have to.
Omnipod® 5 Automated Insulin Delivery
The first wearable, tubeless, hybrid closed loop system that integrates with the leading sensor brands∞, for your patients with type 1 diabetes (T1D) aged 2 years and older.
∞Compatible with Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus sensors
Innovation at its best with three simple parts!
Screen image is an example for illustrative purposes only. Pod and sensors shown without necessary adhesive. Sensors sold separately and require a separate prescription.
Omnipod 5 is compatible with select sensors, so people with diabetes can experience the freedom of automated insulin delivery and improved time in range!1,2
Omnipod 5 in clinicial trials:1,2
Increased
time in range
Reduced
HbA1c
Helped protect against highs and lows
All this without multiple daily injections, insulin pump tubing, and routine finger-stick testing.†
Training at your fingertips
Whether you’re new to Omnipod or ready to deepen your knowledge, our expert-led educational webinars and Within Range: Demystifying Diabetes Tech podcast provide practical guidance on prescribing and supporting Omnipod 5 in clinical practice.
Hear experiences from some of the first Omnipod® 5 Podders
Stay in the loop
Sign up for updates on product enhancements and training and education sessions in your country.
HbA1c, Haemoglobin A1c; HCP, healthcare professional.
† Bolus required for meals and corrections. If your glucose alerts and readings from the sensor do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
§Compatible with the Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus Sensors. Sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. The Dexcom Sensors must be used with the respective Dexcom mobile app. The Dexcom receiver is not compatible. Devices compatible with Dexcom apps can be found at https://www.dexcom.com/compatibility.
1. Brown SA, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5 = 64.7% vs. 73.9%, 52.5% vs. 68.0%, respectively (p<0.0001). Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs. 6.78% or 55 mmol/mol vs. 51 mmol/mol, p<0.0001; 7.67% vs. 6.99%or 60 mmol/mol vs. 53 mmol/mol), p<0.0001). Mean time in hyperglycaemic range (>10.0 mmol/L or >180 mg/dL as measured by CGM) in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs. 29.7%, p<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL as measured by CGM) in adults/adolescents and children ST vs. 3-mo Omnipod 5 = 1.89% vs. 1.32% (p<0.0001) and 2.21%, vs. .78% (p<0.0456), respectively. In a 3-month clinical study, 3 case of severe hypoglycaemia and 1 case of diabetic ketoacidosis (DKA) were reported during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction.
2. Sherr JL, et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use: 7.4% vs. 6.9% or 57 mmol/mol vs. 53 mmol/mol; (p<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs. 68.1%, p<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, p<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs. Omnipod 5: 2.46%, p<0.0001.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog®, Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Admelog/Insulin lispro Sanofi U-100 insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.
† Bolus required for meals and corrections. If your glucose alerts and readings from the sensor do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
§Compatible with the Dexcom G6, Dexcom G7 and FreeStyle Libre 2 Plus Sensors. Sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. The Dexcom Sensors must be used with the respective Dexcom mobile app. The Dexcom receiver is not compatible. Devices compatible with Dexcom apps can be found at https://www.dexcom.com/compatibility.
1. Brown SA, et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70-180 mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5 = 64.7% vs. 73.9%, 52.5% vs. 68.0%, respectively (p<0.0001). Mean HbA1c: ST vs. Omnipod 5 use in adults/adolescents (14-70 yrs) and children (6-13.9 yrs), respectively (7.16% vs. 6.78% or 55 mmol/mol vs. 51 mmol/mol, p<0.0001; 7.67% vs. 6.99%or 60 mmol/mol vs. 53 mmol/mol), p<0.0001). Mean time in hyperglycaemic range (>10.0 mmol/L or >180 mg/dL as measured by CGM) in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs. 29.7%, p<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL as measured by CGM) in adults/adolescents and children ST vs. 3-mo Omnipod 5 = 1.89% vs. 1.32% (p<0.0001) and 2.21%, vs. .78% (p<0.0456), respectively. In a 3-month clinical study, 3 case of severe hypoglycaemia and 1 case of diabetic ketoacidosis (DKA) were reported during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction.
2. Sherr JL, et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean HbA1c as measured in very young children, ST vs. Omnipod 5 use: 7.4% vs. 6.9% or 57 mmol/mol vs. 53 mmol/mol; (p<0.0001). Mean time in range (3.9-10.0 mmol/L or 70-180 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs. 68.1%, p<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180 mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, p<0.0001, respectively. Mean time in hypoglycaemic range (<3.9 mmol/L or <70 mg/dL as measured by CGM) ST = 3.43% vs. Omnipod 5: 2.46%, p<0.0001.
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin. The Omnipod 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog®, Trurapi®/Truvelog®/Insulin aspart Sanofi®, Kirsty®, and Admelog/Insulin lispro Sanofi U-100 insulin. Refer to the Omnipod® 5 Automated Insulin Delivery System User Guide and www.omnipod.com/safety for complete safety information including indications, contraindications, warnings, cautions, and instructions.